MES upgrade tactic: Slay the tweak dragon

Process data are becoming as important as the product itself in drug manufacturing, says the lead engineer on a multi-site implementation of a manufacturing execution system--no process documentation, no product release. So Hoffmann-La Roche is automating across eight sites using the Rockwell Automation MES Core.

Batch data-collection methods pale in comparison to those of an MES, reflecting the current regulatory expectation for mastery of not just process but also process measurement. There's a corporate mandate, too, for greater global operational consistency. The means for serving both masters are centralized best practices and error reduction--all for the end of "significant cost savings," says Robert Fretz in a trade magazine interview.

Fretz, who heads up the MES program as part of Roche's Pharma Global Engineering group, says the centralized approach lets him collect experiences and best practices from all sites into one system, for the benefit of all. It also aligns business processes to uniform compliance and efficiency standards.

One of his key implementation tactics is to keep customization to a minimum. "Although we are challenged to reach less than 10% customizations by the different type of site operations (solids, parenterals, packaging), having too many customizations will lead to being stuck with an older version [of the MES] as costs for upgrades are getting prohibitively high," says Fretz.

- read the interview

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.